Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Nurix Therapeutics (NRIX) Treasury Shares: 2019-2024

Historic Treasury Shares for Nurix Therapeutics (NRIX) over the last 6 years, with Nov 2024 value amounting to $2.0 million.

  • Nurix Therapeutics' Treasury Shares rose 28.99% to $2.7 million in Q3 2025 from the same period last year, while for Aug 2025 it was $2.7 million, marking a year-over-year increase of 28.99%. This contributed to the annual value of $2.0 million for FY2024, which is 56.98% up from last year.
  • Nurix Therapeutics' Treasury Shares amounted to $2.0 million in FY2024, which was up 56.98% from $1.2 million recorded in FY2023.
  • In the past 5 years, Nurix Therapeutics' Treasury Shares ranged from a high of $2.0 million in FY2024 and a low of $4,869 during FY2020.
  • Over the past 3 years, Nurix Therapeutics' median Treasury Shares value was $1.2 million (recorded in 2023), while the average stood at $1.3 million.
  • Per our database at Business Quant, Nurix Therapeutics' Treasury Shares plummeted by 69.17% in 2020 and then surged by 3,824.12% in 2022.
  • Yearly analysis of 5 years shows Nurix Therapeutics' Treasury Shares stood at $4,869 in 2020, then soared by 310.76% to $20,000 in 2021, then spiked by 3,824.12% to $784,824 in 2022, then soared by 58.77% to $1.2 million in 2023, then surged by 56.98% to $2.0 million in 2024.